Wasatch Advisors Inc Athira Pharma, Inc. Transaction History

Wasatch Advisors Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$1.92 - $2.71 $2.49 Million - $3.51 Million	1,296,128 New	1,296,128 $3.43 Million
Q2 2022 Aug 12, 2022	SELL	$2.74 - $13.43 $3.49 Million - $17.1 Million	-1,274,791 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$8.96 - $13.51 $290,017 - $437,291	32,368 Added 2.61%	1,274,791 $17.2 Million
Q4 2021 Feb 15, 2022	BUY	$9.17 - $16.39 $3.17 Million - $5.67 Million	346,140 Added 38.62%	1,242,423 $16.2 Million
Q3 2021 Nov 12, 2021	SELL	$9.15 - $11.09 $2.99 Million - $3.62 Million	-326,501 Reduced 26.7%	896,283 $8.41 Million
Q2 2021 Aug 12, 2021	BUY	$10.24 - $20.87 $4.25 Million - $8.65 Million	414,569 Added 51.29%	1,222,784 $12.5 Million
Q1 2021 May 10, 2021	BUY	$16.9 - $29.77 $13.7 Million - $24.1 Million	808,215 New	808,215 $14.9 Million

16.9M

112K

68K

Ticker ATHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,817,700
Market Cap $23.4M
Description
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...

Get notified when there are updates to the investment portfolio of Wasatch Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Wasatch Advisors Inc with notifications on news.